#United States #New York #Class Action #Levi & Korsinsky #Altimmune

Investors in Altimmune, Inc. Encouraged to Join Class Action Lawsuit

Recent developments concerning Altimmune, Inc. (NASDAQ: ALT) have prompted a call to action for shareholders who have faced financial losses. Levi & Korsinsky, LLP is actively notifying investors about a pending class action lawsuit aimed at recouping losses due to alleged securities fraud that occurred between August 10, 2023, and June 25, 2025. If you are a shareholder of Altimmune and have faced a loss during this period, now is the time to seek justice and possibly recover your investments.

Details of the Class Action Lawsuit

The lawsuit, as defined by Levi & Korsinsky, encompasses individuals who may have been adversely affected by actions taken by the company and its representatives. The allegations stem from a failure to achieve scientific legitimacy in the results of the IMPACT Phase 2b MASH trial concerning Pemvidutide. On June 26, 2025, Altimmune publicly released results that fell short of expectations, revealing a lack of statistical significance in key measures, particularly relevant to the treatment of fibrosis.

On the eve of this release, Altimmune’s stock was trading at $7.71 per share. However, the subsequent announcement of disappointing trial outcomes led to an alarming 53.2% decline in stock price, plummeting to $3.61 per share within just one day. This drastic drop has undoubtedly left investors reeling and seeking accountability from the corporation.

How to Get Involved

Shareholders who believe they have incurred losses during the specified period are encouraged to come forward and express their interest in joining the class action lawsuit. Levi & Korsinsky assures potential participants that all costs of legal representation will be covered, meaning there is no financial burden to those involved. Interested parties can access more information and potentially enroll through the firm’s online submission form, or by contacting Joseph E. Levi, Esq. directly at (212) 363-7500.

Legal Expertise

With over 20 years of experience in securities litigation, Levi & Korsinsky has established itself as a formidable entity in the realm of shareholder rights. By successfully recovering hundreds of millions of dollars for investors, the firm maintains a strong record in complex legal battles. For seven consecutive years, it has ranked within the top echelons of the ISS Securities Class Action Services' report—an accolade underscoring its credibility and commitment to serving its clients.

Moving Forward

For those who have experienced losses attributable to the alleged misconduct by Altimmune, the opportunity to participate in this lawsuit remains open. A deadline has been set for October 6, 2025, for investors to request court appointment as lead plaintiffs. However, involvement in the lawsuit does not necessitate serving in this capacity to share in potential recoveries.

Contact Information

For additional inquiries or to discuss your eligibility to participate, reach out to Levi & Korsinsky, LLP at:

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

This is a significant moment for shareholders of Altimmune, Inc. Join the movement to hold corporate accountability and potentially recover what is rightfully yours.